ArunA has built a comprehensive intellectual property portfolio encompassing key aspects of exosome-based therapeutics.
Coupled with proprietary manufacturing methods, the company is set to develop transformational therapeutics across a range of CNS and neurodegenerative disorders.
We are actively seeking partnerships in the stroke and neural degenerative disease space, and also seeking partners in drug delivery and gene therapy.
- Novel non-cellular biologic approach
- Exploiting complex pathophysiologic pathways to address acute and chronic neurologic conditions
- Proven neural protection and anti-inflammatory activity
- Poised to advance multiple indications into clinical development
- Consistent, scalable exosome manufacturing process
- Strong science platform with continuing leadership by Dr. Steven Stice
- Treatment greatly reduces hemorrhaging within 24 hours post injury
To discuss a potential partnership with ArunA, please contact Tracey Stice at email@example.com.